Article
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Antiviral therapy - 1 Dec 2002
Gibb Diana M, Walker A Sarah, Kaye Steve, De Rossi Anita, Ait-Khaled Mounir, Pillay Deenan, Muñoz-Fernandez Maria Angeles, Loveday Clive, Compagnucci Alexandra, Dunn David T, Babiker Abdel G
Abstract excerpt
PURPOSE AND METHODS: To describe the evolution of resistance to zidovudine (ZDV), lamivudine (3TC), abacavir (ABC) and nelfinavir (NFV), 113 previously untreated children in the PENTA 5 trial had resistance assayed at baseline, rebound and/or 24, 48, 72 weeks (VIRCO: phenotyping and genotyping with 'Virtual Phenotype' interpretation). RESULTS: At baseline, few reverse transcriptase mutations and no primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.